Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24542733 | 0.94 | ALDH1A1 (0.52) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL279357 | 0.83 | APP (0.37) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL134443 | 0.82 | IDO1 (0.46) | TSHRAPPTP53 | |
| SCHEMBL12509337 | 0.79 | APP (0.56) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL7968195 | 0.79 | ALDH1A1 (0.56) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL24696625 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL12422435 | 0.77 | LPL (0.40) | ALDH1A1TSHRMAPK1TDP1APP | |
| SCHEMBL20691534 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL308112 | 0.77 | ERN1 (0.41) | ALDH1A1TSHRMAPK1TDP1APP | |
| SCHEMBL15617851 | 0.77 | LPL (0.40) | ALDH1A1TSHRMAPK1TDP1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | claimed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| WO-2023009835-A9 | ANTIBODY CONJUGATES SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-01-04 | — | — | WO | disclosed |
| US-9801851-B2 | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-14 | — | — | US | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | ABL1, BCR, ABL2 | ALDH1A1 2348/4885TSHR 4621/4885MAPK1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.